Clinical Trial Update: A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours [Phase 1]

View source ↗

Summary

Phase I dose-escalation study of subcutaneous ALM201 in patients with advanced ovarian cancer and other solid tumors; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Solid Tumors

Drugs mentioned

• ALM201 (ALM201)

Snippet

Sponsor: Almac Discovery | Conditions: Solid Tumors, Ovarian Cancer | Phase 1 | Status: TERMINATED | Results posted: 2019-09-11